Anti-HER2 biparatopic antibody-drug conjugates and methods of use
US12357701B2 · kind B2 · utility
0Cited by
24References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 23, 2021 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Dec 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.